Radical control of malaria likely requires a vaccine that targets both the asymptomatic liver
stages and the disease-causing blood stages of the human malaria parasite Plasmodium …

A vaccine remains a priority in the global fight against malaria. Here, we report on a single-
center, randomized, double-blind, placebo and adjuvant-controlled, dose escalation phase …

Protecting against both liver and blood stages of infection is a long-sought goal of malaria
vaccine design. Recently, we described the use of replication-defective viral vaccine vectors …

An efficacious malaria vaccine remains elusive despite concerted efforts. Using the
Plasmodium yoelii murine model, we previously reported that immunization with the C …

The most widespread Plasmodium species, Plasmodium vivax, poses a significant public
health threat. An effective vaccine is needed to reduce global malaria burden. Of the …

Efficacy trials of antibody-inducing protein-in-adjuvant vaccines targeting the blood-stage
Plasmodium falciparum malaria parasite have so far shown disappointing results. The …

The development of protective vaccines against many difficult infectious pathogens will
necessitate the induction of effective antibody responses. Here we assess humoral immune …

Background Two current leading malaria blood-stage vaccine candidate antigens for
Plasmodium falciparum, the C-terminal region of merozoite surface protein 1 (MSP119) and …

Background The development of an asexual blood stage vaccine against Plasmodium
falciparum malaria based on the major merozoite surface protein-1 (MSP1) antigen is …

Background Overcoming antigenic diversity is a key challenge in the development of
effective Plasmodium falciparum malaria vaccines. Strategies that promote the generation of …